Abstract: The present disclosure provides methods of identifying patients who have partial or total resistance to HIF-2 inhibitors or who develop partial or total resistance to HIF-2 inhibitors after treatment and providing suitable treatment to these patients.

Abstract: Aspects of the disclosure relate to compositions and methods for amplifying and/or detecting one or more target nucleic acid sequences (e.g., a nucleic acid sequence of one or more pathogens) in a biological sample obtained from a subject. In some embodiments, the pathogens are viral, bacterial, fungal, parasitic, or protozoan pathogens, such as SARS-CoV-2 or an influenza virus. In some embodiments, the methods comprise isothermal amplification of a target nucleic acid and subsequent detection of the amplification products.

Abstract: The present disclosure provides methods for the identification, characterization and ranking of putative tau monomer stabilizing agents. Specifically, the disclosure provides methods for assessing the capability of a test compound to stabilize a tau monomer, methods of prioritizing a plurality of test compounds from a library identified as tau monomer stabilizing agents, methods of screening a test compound library to identify tau monomer stabilizing agents, and a kit providing the reagents to perform the described methods.

Abstract: The present disclosure is directed to methods and compositions for the prediction and treatment of immunotherapy-induced toxicities, as well as improved methods for the treatment of cancer with immunotherapies.

Abstract: Embodiments of the disclosure encompass methods and compositions related to cell therapy treatment, including for cancer. In specific embodiments, the disclosure concerns adoptive cell therapy cancer treatment in which tumor-1 infiltrating lymphocytes and/or engineered T cells are modified to increase their efficacy as a cancer treatment. In specific cases, the cells are engineered for knock out of one or more genes, such as Signaling Threshold Regulating Transmembrane Adaptor 1 (SIT1), Bone Marrow Stromal Cell Antigen 2 (BST2), and/or programmed cell death protein 1 (PD-1).

Abstract: The present disclosure describes the use of ectopic SOX2 to promote nerve growth and regeneration, particularly in the context of nerve deficit stemming from trauma and disease, by reprogramming non-nerve cells into neuronal cells. In particular, the disclosure provides for the use of SOX2 therapy, optionally combined with neurogenic growth factors, to treat nerve deficit conditions.

Abstract: Disclosed here are uses of autophagy inhibitors for treating a subject at risk of suffering from an aneurysm. The present disclosure demonstrates that autophagy plays a role in THSD1-mediated focal adhesion stability and aneurysm formation and characterizes molecular targets for therapeutic intervention.

Abstract: A shunt operable to be implanted on an eye is provided. The shunt includes a vein fluidic channel operable to be in fluid communication with an interior of the eye and operable to receive aqueous fluid from the interior of the eye. A body is fluidly coupled with the vein fluidic channel. A valve is disposed within the body and is operable to regulate intraocular pressure in the eye by opening and closing based on pressure from the aqueous fluid. A plurality of outlets are in fluid communication with the body opposite the vein fluidic channel in relation to the valve. The outlets are operable to release the aqueous fluid to the sclera of the eye.

Abstract: We disclose a method, comprising administering, to a patient suffering from a cancer, a composition comprising a compound containing a gold atom; and administering, to a portion of the patient's body in which the cancer is present, radiation. We also disclose a kit comprising a composition comprising a compound containing a gold atom; and instructions to perform the method.

Abstract: Disclosed are systems and techniques for increasing heat transfer from a substrate to a working fluid. The systems may include a substrate comprising a plurality of grooves or cavities on at least one external surface. The system may also include an infusing liquid filling at least a majority of the plurality of grooves. The system may also include a working fluid configured to flow parallel to the external surface.

Abstract: Various embodiments provide for deep learning-based architectures and design methodologies for an orthogonal frequency division multiplexing (OFDM) receiver under the constraint of one-bit complex quantization. Single bit quantization greatly reduces complexity and power consumption in the receivers, but makes accurate channel estimation and data detection difficult. This is particularly true for OFDM waveforms, which have high peak-to average (signal power) ratio in the time domain and fragile subcarrier orthogonality in the frequency domain. The severe distortion for one-bit quantization typically results in an error floor even at moderately low signal-to-noise-ratio (SNR) such as 5 dB. For channel estimation (using pilots), various embodiments use novel generative supervised deep neural networks (DNNs) that can be trained with a reasonable number of pilots. After channel estimation, a neural network-based receiver specifically, an autoencoder jointly learns a precoder and decoder for data symbol detection.

Abstract: Aspects of the disclosure relate to a method of treating glioblastoma in a subject comprising administering to the subject a KDM6B inhibitor. In some aspects, the methods are performed in combination with an immunoterhapy. Further aspects relate to a composition comprising a KDM6B inhibitor and an immunotherapy.

Abstract: We disclose a composition, comprising a compound, comprising a melanin precursor that spontaneously synthesizes a melanin when in free form in vivo, and a peptide directly covalently bonded to or indirectly linked to the melanin precursor, wherein the direct covalent bond or indirect link of the peptide to the melanin precursor blocks spontaneous synthesis of the melanin in vivo in the absence of protease activity. We also disclose methods of tumor imaging, tumor detection, diagnosis, and treatment, including methods comprising administering, to a patient suffering from a tumor, the composition; and either surgically resecting the tumor or thermally ablating the tumor, wherein the surgical resection is guided at least in part by contrast imparted by, or the thermally ablating targets cells containing, the melanin, wherein the melanin is spontaneously synthesized in the tumor after administering the composition.

Abstract: The disclosure provides methods and compositions for treating subject having cancers with abnormal WNT signaling, such as APC-deficient cancers. Accordingly, aspects of the disclosure relate to methods for treating APC-deficient cancers comprising administering an inhibitor of TDO2 or of a cytokine activated by TDO2. Additional aspects relate to methods for identifying a cancer as being sensitive to TDO2 inhibition comprising detecting a deficiency in an APC gene and/or measuring an expression level of TDO2.

Abstract: Disclosed are methods of treating a subject, such as those having or at risk of cardiomyopathies, with an effective amount of a recombinant adeno-associated virus (rAAV) virion, the rAAV virion comprising an AAV capsid and an expression cassette comprising a polynucleotide encoding a DWORF polypeptide operatively linked to a promoter. Compositions and kits relating to the same are also disclosed.

Abstract: A computer-implemented technique for training an artificial neural network is disclosed. The technique includes obtaining a training sample for training the artificial neural network; determining multiple sub concepts within the training sample; processing the sub concepts to obtain differential neurons associated with the sub concepts, wherein the differential neurons provide a relative distinction between the sub concepts; integrating the differential neurons to obtain sub concepts neurons, wherein the sub concepts neurons provide an absolute distinction of sub concepts; and integrating the sub concepts neurons to obtain concept neurons that form an output of the neural network.

Abstract: Provided herein are engineered Coronavirus S proteins, such as engineered SARS-CoV-2 S proteins. In some aspects, the engineered S proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of engineered proteins as diagnostics, in screening platforms and/or in vaccine compositions.

Abstract: Embodiments of the disclosure include methods and compositions directed to targeting of cells that express the long form of Bone marrow stromal cell antigen 2 (BST2) protein, including cancer cells that express the long isoform of BST2. In particular embodiments, monoclonal antibodies or functionally active fragments thereof are utilized to target cells that express the long isoform of BST2. The monoclonal antibodies or functionally active fragments thereof may be utilized by themselves or as part of other entities, such as cells or engineered antigen receptors. The disclosure includes methods of treatment, prevention, and/or diagnosis using the encompassed antibodies or functional fragments thereof.

Abstract: Provided herein are antibodies binding to LILRB1 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.

Abstract: The present disclosure relates to antibodies binding to tumor discoidin domain receptor 1 (DDR1) and the uses of the antibodies in detecting and treating cancer.